Delivery Order SPE2DP18D0011-SPE2DP18F6081
Award Date
9/22/18
Potential Completion Date
9/23/19
Potential Value
$94K
Federal Agency
Medical Supply Chain
Awardee
Genentech Usa, Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
South San Francisco, CA 94080, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award (SPE2DP16D0008|0008) was issued by the Medical Supply Chain division of the Defense Logistics Agency (DLA) to Genentech USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, for the delivery of oseltamivir phosphate (the active ingredient in Tamiflu). The $143,455.80 firm fixed-price delivery order contract has a period of performance through September 20, 2017. This award is associated with a larger indefinite delivery contract between Genentech and the...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Genentech USA, Inc., a foreign-owned, for-profit manufacturer of pharmaceuticals and biologics. The $172,070.04 firm fixed-price order is for the antiviral medication oseltamivir phosphate (Tamiflu) under contract SPE2DP16D0008. Genentech supplies a wide range of pharmaceutical products to federal agencies, including the Department of Defense, Department of Health and Human Services, Department of Justice, and Department...
This is a $149,340.18 firm fixed-price delivery order awarded by the Medical Supply Chain division of the Defense Logistics Agency to Genentech USA, Inc., a foreign-owned pharmaceutical manufacturer, for the supply of the antiviral drug oseltamivir phosphate (Tamiflu). The order was placed against Genentech's existing $27.9 million indefinite delivery contract with the Defense Logistics Agency to provide medical supplies and critical pharmaceuticals supporting the Department of Defense's...
This federal contract award, SPE2DP16D0008|0051, was issued by the Defense Logistics Agency (DLA) to Genentech USA, Inc., a foreign-owned, for-profit biotechnology and pharmaceutical manufacturer. The $76,496.94 firm-fixed-price delivery order is for the supply of oseltamivir phosphate, an antiviral medication, with a period of performance through September 11, 2018. Genentech holds several major contract vehicles with federal agencies like the Department of Veterans Affairs and the Department...
This federal contract award, SPE2DP16D0008|0021, was made by the Medical Supply Chain division of the Defense agency to Genentech USA, Inc., a foreign-owned, for-profit manufacturer of pharmaceuticals. The $101,188.26 firm-fixed-price delivery order is for the antiviral medication oseltamivir phosphate, with a performance period ending on September 22, 2017. The award is not associated with a set-aside program. Genentech USA, Inc. is a major supplier of pharmaceuticals and biologics to federal...
This is a $112,687.80 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Genentech USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, for the supply of oseltamivir phosphate, an antiviral medication. The contract is not designated as a set-aside. Genentech holds several key contract vehicles with federal agencies, including a $4.9 billion Federal Supply Schedule with the Department of Veterans Affairs for pharmaceutical products, and a...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Genentech USA, Inc., a foreign-owned, for-profit manufacturer of pharmaceuticals and biologics. The contract is for the supply of oseltamivir phosphate, an antiviral medication, with a total ceiling value of $259,393.47. The contract is a firm-fixed price delivery order with a completion date of September 20, 2017. Genentech is the prime contractor, and no major subcontractors were identified. The contract is...
This is a federal contract award from the Medical Supply Chain of the Department of Defense to Genentech USA, Inc., a foreign-owned, for-profit manufacturer of pharmaceuticals and biologics. The contract is for the delivery of oseltamivir phosphate, an antiviral medication, with a ceiling value of $149,340.18. The contract is a firm-fixed price delivery order placed under an existing vehicle, with an ultimate completion date of September 21, 2017. No set-aside designation was used. Genentech...
This federal contract award was made by the Veterinary Services agency (part of the Department of Agriculture) to Genentech USA, Inc., a foreign-owned, for-profit biotechnology company that manufactures pharmaceuticals. The award is for the delivery of Tamiflu (oseltamivir phosphate) capsules, 75 mg, with a ceiling value of $193,939.20 and a period of performance through December 31, 2020. This appears to be a delivery order issued against a larger contract vehicle, as Genentech holds several...
This is a delivery order under a Federal Supply Schedule contract awarded by the Defense Logistics Agency (DLA) to Genentech USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer. The contract is for the delivery of oseltamivir phosphate, an antiviral medication, with a ceiling value of $8,434,278.00 and a period of performance ending on September 20, 2017. The contract does not have a set-aside designation. Genentech holds several key contract vehicles with federal agencies,...